Sun Pharmaceutical Industries Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sun Pharmaceutical Industries Ltd.
Company hopes a different formulation of its intracanicular insert of cyclosporin might provide longer duration of drug in the eye and better tear production with it.
Top executives at leading local and foreign drug firms in India by and large earned more in 2020-21, while differentials in CEO to median employee remuneration remained stark. With increasing scrutiny by shareholders and lawmakers, experts suggest that pharma should be more mindful of balancing “adequate” C-suite compensation and glaring inequalities.
EU reviewers have recommended five new medicines and a pneumococcal vaccine for EU-wide approval. New uses of several approved medicines have also drawn the thumbs up, while the sponsor of a cancer drug has withdrawn its product from the review process.
Two Indian firms want to terminate specific Phase III trials for molnupiravir, the Merck/ Ridgeback Biotherapeutics’ antiviral in the spotlight as a treatment for mild-to-moderate COVID-19. Should much be read into these plans or is it merely an “administrative closure” that is being sought?
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Aditya Acquisition Company ltd
- Caraco Pharmaceutical Laboratories, Ltd.
- DUSA Pharmaceuticals, Inc.
- InSite Vision, Inc.
- JSC Biosintez
- Ocular Technologies
- Pola Pharma Inc.
- Ranbaxy Laboratories Limited
- Ranbaxy Solus
- Solus Care
- Sun Ophthalmics
- Sun Pharma Global FZE